Abetimus

CAS: 167362-48-3 F: C1632H2100N610O97P156S4 W: 50742.05

Abetimus (LJP 394 free base) is an immunosuppressant consisting of four double-stranded DNA (dsDNA) oligonucleotides. Ab

Contact QiTai

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity	Abetimus (LJP 394 free base) is an immunosuppressant consisting of four double-stranded DNA (dsDNA) oligonucleotides. Abetimus is capable of crosslinking anti-dsDNA antibodies on the surface of B cells, and decreases anti-dsDNA antibodies levels. Abetimus has the potential for research of systemic lupus erythematosus[1].
Invitro	Administration of Abetimus (LJP 394 free base) is thought to reduce circulating anti-dsDNA Abs by at least two mechanisms. First, Abetimus (LJP 394 free base) acutely depletes circulating anti-dsDNA antibodies, presumably by forming small, soluble complexes that do not appear to result in significant activation of the complement system. Second, Abetimus (LJP 394 free base) binds B cells without T-cell activation, resulting in their apoptosis and reduced anti-dsDNA antibody production. In fact, Abetimus (LJP 394 free base) appears to induce B-cell tolerance by crosslinking anti-dsDNA surface immunoglobulin receptors on B cells and triggering the signal transduction pathways that lead to B-cell anergy or apoptosis[1].
In Vivo	Abetimus (LJP 394 free base) proves effective in suppressing anti-dsDNA-mediated pathologies in male BXSB mice, a model for systemic lupus. Mice dosed with Abetimus (3-300 μg/mouse) i.v. twice weekly, starting around nine weeks of age, has significantly lower titers of anti-dsDNA, lower numbers of anti-dsDNA-secreting spleen cells and less adverse renal histopathology than control mice[2]. Abetimus has a pharmacokinetic half-life ranging from 40 min to 1 h in mice[1].
Name	Abetimus
CAS	167362-48-3
Formula	C1632H2100N610O97P156S4
Molar Mass	50742.05
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Marta Mosca, et al. LJP-394 (abetimus sodium) in the treatment of systemic lupus erythematosus. Expert Opin Pharmacother. 2007 Apr;8(6):873-9. [2]. S M Coutts, et al. Pharmacological intervention in antibody mediated disease. Lupus. 1996 Apr;5(2):158-9.

n-Propyl-amine-d7 (Hydrochloride)